Peripheral Vascular Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Peripheral Stents, PTA Balloons, Catheters, Endovascular Aneurysm Repair Stent Grafts, Plaque Modification Devices, Peripheral Accessories, Inferior Vena Cava Filters, Hemodynamic Flow Alteration Devices), By End User (Hospitals, Clinics, Ambulatory Surgical Centers), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 10.71 Billion
CAGR (2026-2031)	7.02%
Fastest Growing Segment	Hospitals
Largest Market	North America
Market Size (2031)	USD 16.09 Billion

Market Overview

The Global Peripheral Vascular Devices Market is projected to grow from USD 10.71 Billion in 2025 to USD 16.09 Billion by 2031 at a 7.02% CAGR. Peripheral vascular devices encompass a range of interventional medical instruments, including stents, catheters, angioplasty balloons, and atherectomy systems, designed to treat vascular diseases affecting blood vessels outside the heart and brain. The market is primarily supported by the escalating global prevalence of peripheral artery disease, which is intrinsically linked to an aging population and the rising incidence of lifestyle-dependent conditions such as diabetes and obesity. Additionally, the fundamental shift in clinical preference from open surgical revascularization to minimally invasive endovascular procedures acts as a robust catalyst for volume growth, as these methods offer reduced recovery times and lower complication rates for patients.

Despite these strong growth fundamentals, the market faces a significant challenge regarding the high rate of underdiagnosis and low disease awareness among the general population. Delayed detection often results in disease progression to stages where device-based intervention is no longer viable, thereby limiting the addressable market size. According to the Society for Vascular Surgery, in 2025, more than 68% of Americans were unaware of peripheral artery disease. This critical gap in patient education significantly impedes early screening efforts and restricts the utilization of peripheral vascular interventions globally.

Key Market Drivers

The escalating incidence of diabetes and lifestyle-related comorbidities serves as a primary engine for the Global Peripheral Vascular Devices Market. Chronic hyperglycemia and obesity significantly accelerate the progression of atherosclerosis, directly increasing the susceptibility of patients to peripheral artery disease (PAD) and critical limb ischemia. This epidemiological trend creates a sustained demand for interventional therapies, as vascular complications necessitate frequent revascularization procedures to prevent amputation. According to the International Diabetes Federation, 2025, in the 'IDF Diabetes Atlas 11th Edition', approximately 11.1% of the global adult population is living with diabetes, a figure that underscores the vast and expanding patient pool requiring long-term vascular management.

Concurrently, the market is being propelled by a paradigm shift toward minimally invasive endovascular interventions and continuous technological innovation. Clinicians are increasingly favoring catheter-based techniques over traditional open surgery due to superior patient outcomes, including shorter hospital stays and reduced procedural risks. This transition is further supported by advancements in device capabilities, such as drug-coated balloons and next-generation stent platforms, which drive higher procedural volumes. According to Abbott, January 2025, in the 'Fourth-Quarter and Full-Year 2024 Results', the company's Medical Devices segment achieved an organic sales increase of 14.0%, reflecting strong adoption of its interventional technologies. Additionally, according to Medtronic, May 2025, in the 'Fiscal Year 2025 Financial Results', the Cardiovascular Portfolio generated $12.481 billion in annual revenue, highlighting the robust global expenditure on vascular care solutions.

Download Free Sample Report

Key Market Challenges

The high rate of underdiagnosis and low disease awareness fundamentally restricts the revenue potential of the global peripheral vascular devices market by limiting the volume of treatable patients. Device manufacturers depend on the early identification of candidates for minimally invasive interventions, such as angioplasty or stenting. However, because symptoms like leg pain are frequently dismissed by patients as normal signs of aging, a vast segment of the affected population fails to seek medical advice until the condition becomes severe. This delay causes a significant contraction in the addressable market, as missed diagnoses directly translate into fewer procedural opportunities for utilizing vascular technologies.

This challenge is intensified by a lack of proactive clinical engagement with high-risk populations. According to the Society for Cardiovascular Angiography and Interventions, in 2025, 80% of Black and Hispanic adults reported that a healthcare provider had never discussed peripheral artery disease with them. Such gaps in patient-provider communication create a barrier to entry for device usage, as the condition remains unidentified and untreated in a large demographic. Consequently, the market experiences suppressed growth rates, as the actual clinical demand falls well short of the prevalence-based potential.

Key Market Trends

The migration of peripheral vascular procedures to Ambulatory Surgical Centers (ASCs) and Office-Based Labs (OBLs) represents a structural transformation driven by favorable reimbursement models and operational efficiency. This shift allows for reduced overhead costs while maintaining clinical safety for interventions like angioplasty, compelling manufacturers to tailor commercial models to independent facilities rather than large hospital networks. According to the American College of Cardiology, November 2025, in the 'Studies Examine Current Treatments and Trends For Peripheral Vascular Interventions', an analysis of fee-for-service claims revealed that the proportion of total revascularizations performed in ASC and OBL environments has surged to reach 47% of the total procedural volume.

Simultaneously, the widespread uptake of Intravascular Lithotripsy (IVL) is redefining the treatment of heavily calcified lesions that complicate endovascular outcomes. Unlike traditional balloons, IVL utilizes sonic pressure waves to fracture calcium deposits within the vessel wall, optimizing vessel compliance prior to stent deployment and enabling successful revascularization in complex cases. This technology has become essential for treating advanced peripheral artery disease, directly fueling revenue expansion for major industry players. According to Johnson & Johnson, October 2025, in the 'Q3 2025 Results', the Cardiovascular segment delivered a reported sales increase of 12.6%, a growth trajectory primarily attributed to the accelerating global demand for the Shockwave intravascular lithotripsy platform.

Segmental Insights

The hospital segment is projected to emerge as the fastest-growing category in the global peripheral vascular devices market. This expansion is primarily driven by the increasing volume of patients requiring complex endovascular procedures that mandate the specialized infrastructure and catheterization laboratories found in hospital settings. Additionally, reimbursement frameworks established by institutions such as the Centers for Medicare & Medicaid Services often favor inpatient care for major surgical interventions, which supports higher procedural volumes. These factors collectively ensure that hospitals remain the primary point of care, driving sustained demand for vascular devices within this sector.

Regional Insights

North America leads the Global Peripheral Vascular Devices Market, driven by a robust healthcare infrastructure and a growing incidence of peripheral artery disease among an aging population. The region benefits significantly from the presence of major medical device manufacturers that prioritize innovation in minimally invasive therapies. Furthermore, favorable reimbursement schemes and established approval pathways by the U.S. Food and Drug Administration (FDA) facilitate the timely introduction of effective solutions. This combination of high clinical demand, technological accessibility, and regulatory clarity secures North America’s position as the primary revenue generator in the global sector.

Recent Developments

• In November 2024, Medtronic released new clinical data and a systematic literature review at the Vascular InterVentional Advances (VIVA) conference, reinforcing the safety and effectiveness of atherectomy for peripheral arterial disease. The Total REALITY study presented retrospective outcomes comparing directional atherectomy combined with drug-coated balloons versus balloon predilatation alone in treating long, calcified femoropopliteal lesions. The company highlighted that this comprehensive analysis, which included over 300 published studies, provided robust evidence supporting the utility of atherectomy as a critical component of the endovascular treatment algorithm for complex peripheral vascular conditions.
• In September 2024, Boston Scientific Corporation finalized its acquisition of Silk Road Medical, Inc., a medical device company known for its platform dedicated to stroke prevention during carotid artery procedures. The transaction, reflecting an enterprise value of approximately $1.18 billion, added the Transcarotid Artery Revascularization (TCAR) procedure to Boston Scientific’s vascular technology offerings. This minimally invasive approach was designed to treat carotid artery disease by temporarily reversing blood flow to prevent plaque from dislodging and reaching the brain. The integration aimed to expand physician access to this innovative technology and improve patient outcomes within the peripheral vascular intervention landscape.
• In May 2024, Johnson & Johnson completed the acquisition of Shockwave Medical, a company specializing in intravascular lithotripsy technology, in a transaction valued at approximately $13.1 billion. This strategic move integrated Shockwave’s catheter-based devices, which use sonic pressure waves to disrupt calcified lesions, into Johnson & Johnson’s MedTech portfolio. The collaboration was intended to accelerate the company’s expansion into high-growth cardiovascular intervention segments, specifically for the treatment of coronary and peripheral artery disease. The addition of this technology complemented the company's existing heart recovery and electrophysiology solutions, aiming to address unmet patient needs in complex vascular care.
• In April 2024, Abbott announced the U.S. Food and Drug Administration (FDA) approval of the Esprit BTK Everolimus Eluting Resorbable Scaffold System, a significant advancement in the Global Peripheral Vascular Devices Market. This device was introduced as a breakthrough innovation for treating chronic limb-threatening ischemia in arteries below the knee. Unlike traditional metal stents that remain in the body permanently, this system was designed to keep the vessel open and deliver a drug to support healing before completely dissolving over time. The approval was supported by the LIFE-BTK clinical trial, which demonstrated that the scaffold offered superior outcomes compared to balloon angioplasty, the conventional standard of care for severe peripheral artery disease.

Key Market Players

• Abbott Laboratories
• AngioScore Inc.
• Edward Lifesciences Corporation
• Medtronic Plc.
• Teleflex Inc.
• Volcano Corporation
• Boston Scientific Corporation
• Cook Group Inc.

By Type	By End User	By Region
Peripheral Stents PTA Balloons Catheters Endovascular Aneurysm Repair Stent Grafts Plaque Modification Devices Peripheral Accessories Inferior Vena Cava Filters Hemodynamic Flow Alteration Devices	Hospitals Clinics Ambulatory Surgical Centers	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Peripheral Vascular Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Peripheral Vascular Devices Market, By Type:

• Peripheral Stents
• PTA Balloons
• Catheters
• Endovascular Aneurysm Repair Stent Grafts
• Plaque Modification Devices
• Peripheral Accessories
• Inferior Vena Cava Filters
• Hemodynamic Flow Alteration Devices

• Peripheral Vascular Devices Market, By End User:

• Hospitals
• Clinics
• Ambulatory Surgical Centers

• Peripheral Vascular Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE